Cite
Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
MLA
Auner, Holger W., et al. Melphalan 140 Mg/m(2) or 200 Mg/m(2) for Autologous Transplantation in Myeloma: Results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) Study. A Report by the EBMT Chronic Malignancies Working Party. Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..87a0f580bc9f604d6d33fffc1ab556ed&authtype=sso&custid=ns315887.
APA
Auner, H. W., Iacobelli, S., Sbianchi, G., Knol-Bout, C., Blaise, D., Russell, N. H., Schaap, N. P. M., Garderet, L., & Kroeger, N. (2018). Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
Chicago
Auner, Holger W., S. Iacobelli, Giulia Sbianchi, Cora Knol-Bout, D. Blaise, Nigel H. Russell, N.P.M. Schaap, L. Garderet, and Nicolaus Kroeger. 2018. “Melphalan 140 Mg/m(2) or 200 Mg/m(2) for Autologous Transplantation in Myeloma: Results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) Study. A Report by the EBMT Chronic Malignancies Working Party,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..87a0f580bc9f604d6d33fffc1ab556ed&authtype=sso&custid=ns315887.